Sign Up Today and Learn More About Ten63 Therapeutics Stock
Invest in or calculate the value of your shares in Ten63 Therapeutics or other pre-IPO companies through EquityZen's platform.
Ten63 Therapeutics Stock (TSTT)
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the world’s most lethal diseases.
About Ten63 Therapeutics Stock
Founded
2017
Headquarters
Durham, NC, US
Industries
Software, Artificial Intelligence, Data and Analytics
Ten63 Therapeutics Press Mentions
Stay in the know about the latest news on Ten63 Therapeutics
Ten63 Therapeutics Closes Strategic Financing, Bringing Total Funding to More Than $45M to Scale the Next-Generation of Artificial Intelligent Drug Discovery
vcaonline • Feb 24, 2026
Ten63 Therapeutics Secures Strategic Investment from Chugai Venture Fund and Gates Foundation
venturecapital • Feb 21, 2026
Financings for Feb. 20, 2026
bioworld • Feb 21, 2026
Ten63 Therapeutics Secures New Funding
vcnewsdaily • Feb 21, 2026
Ten63 Therapeutics: Strategic Funding Raised For AI Drug Discovery Platform
pulse2 • Feb 20, 2026
Ten63 Therapeutics Management
Leadership team at Ten63 Therapeutics
Co-founder and CTO
Mark Hallen
Director Of Chemistry
Stephen Thomson
Join now and verify your accreditation status to gain access to:
- Ten63 Therapeutics Current Valuation
- Ten63 Therapeutics Stock Price
- Ten63 Therapeutics Management
- Available deals in Ten63 Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Ten63 Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Ten63 Therapeutics Revenue and Financials
- Ten63 Therapeutics Highlights
- Ten63 Therapeutics Business Model
- Ten63 Therapeutics Risk Factors
- Ten63 Therapeutics Research Report from SACRA Research
Trading Ten63 Therapeutics Stock
How to invest in Ten63 Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Ten63 Therapeutics through EquityZen funds. These investments are made available by existing Ten63 Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Ten63 Therapeutics stock?
Shareholders can sell their Ten63 Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
